Diagnostic Accuracy and Management of Vulvovaginal Candidiasis

Diagnostic Pitfalls

Fewer than 50 % of women who receive antifungal therapy for presumed vulvovaginal candidiasis (VVC) have an objective laboratory confirmation of infection, leading to widespread overtreatment of asymptomatic colonization. 1, 2

Direct microscopy detects Candida in only about 57 % of true VVC cases, reflecting limited sensitivity. 3
Approximately half of patients with confirmed VVC have a negative microscopy result, underscoring the risk of false‑negative diagnoses. 1, 2
Microscopy identifies yeast presence but cannot differentiate between asymptomatic colonization and symptomatic infection. 1

Fungal culture requires a minimum of 48–72 hours to yield results, delaying definitive diagnosis. 1, 2

PCR testing offers superior diagnostic performance, with a sensitivity of roughly 91 % and specificity of about 94 % compared with clinical assessment alone. 3
For Candida detection, PCR provides a positive predictive value of ~87 % and a negative predictive value of ~96 %, enhancing confidence in ruling in or out infection. 3
Despite its high accuracy, PCR results must still be interpreted in the context of patient‑reported symptoms to confirm VVC. 1, 3

Asymptomatic Candida colonization should not be treated with antifungal agents, as therapy offers no clinical benefit and may promote resistance. 1, 2
Antifungal treatment is warranted only when both (a) a positive laboratory detection of Candida (microscopy, culture, or PCR) and (b) documented vulvovaginal symptoms consistent with VVC are present. 1

Initiating antifungal therapy based solely on a positive culture or PCR without accompanying symptoms results in unnecessary drug exposure and contributes to emerging resistance. 1, 2
Relying exclusively on clinical judgment without laboratory confirmation leads to misdiagnosis in more than 50 % of cases, causing both over‑ and under‑treatment. 1